UBS Group Issues Positive Forecast for Sight Sciences (NASDAQ:SGHT) Stock Price

Posted by Stanley Muller on Aug 6th, 2026

Sight Sciences (NASDAQ:SGHT – Get Free Report) had its price objective hoisted by UBS Group from $7.00 to $8.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s price objective indicates a potential upside of 15.24% from the company’s current price.

Several other research firms have also issued reports on SGHT. Weiss Ratings lowered shares of Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. Citigroup raised their price objective on shares of Sight Sciences from $5.15 to $6.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $7.88.

View Our Latest Research Report on SGHT

Sight Sciences Stock Up 25.1%

SGHT traded up $1.39 during trading on Thursday, hitting $6.94. 666,782 shares of the company’s stock were exchanged, compared to its average volume of 269,861. Sight Sciences has a fifty-two week low of $3.19 and a fifty-two week high of $9.24. The stock has a market cap of $377.71 million, a P/E ratio of -9.80 and a beta of 2.38. The business’s 50 day moving average is $5.14 and its two-hundred day moving average is $4.90. The company has a quick ratio of 5.48, a current ratio of 5.86 and a debt-to-equity ratio of 0.68.

Sight Sciences (NASDAQ:SGHT – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.10. The firm had revenue of $23.39 million for the quarter, compared to the consensus estimate of $21.72 million. Sight Sciences had a negative net margin of 46.83% and a negative return on equity of 52.34%. As a group, equities analysts expect that Sight Sciences will post -0.6 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Jeremy B. Hayden sold 12,733 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $5.51, for a total value of $70,158.83. Following the completion of the transaction, the insider directly owned 357,037 shares in the company, valued at approximately $1,967,273.87. This trade represents a 3.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Paul Badawi sold 28,684 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $5.42, for a total transaction of $155,467.28. Following the transaction, the chief executive officer directly owned 6,122,472 shares of the company’s stock, valued at approximately $33,183,798.24. This represents a 0.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 58,566 shares of company stock valued at $318,827. Corporate insiders own 30.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. SCS Capital Management LLC bought a new position in shares of Sight Sciences in the second quarter worth $488,000. Bank of New York Mellon Corp bought a new stake in Sight Sciences during the second quarter valued at $495,000. GSA Capital Partners LLP purchased a new position in Sight Sciences during the second quarter worth about $908,000. Renaissance Technologies LLC grew its position in Sight Sciences by 6.3% during the first quarter. Renaissance Technologies LLC now owns 293,358 shares of the company’s stock worth $1,106,000 after buying an additional 17,458 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Sight Sciences by 13.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 341,681 shares of the company’s stock worth $1,288,000 after acquiring an additional 40,346 shares during the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Key Sight Sciences News

Here are the key news stories impacting Sight Sciences this week:

Positive Sentiment: Q2 results exceeded expectations: Sight Sciences reported an adjusted loss of $0.08 per share, better than analysts’ expected loss of $0.15-$0.18 and improved from a $0.23 loss a year earlier. Revenue of $23.39 million also surpassed the $21.72 million consensus estimate. Sight Sciences Reports Q2 Loss, Tops Revenue Estimates
Positive Sentiment: 2026 outlook was raised: The company now expects full-year revenue of $88 million to $92 million, above the roughly $86.1 million Wall Street forecast, while also reducing its adjusted operating-expense guidance. The improved outlook suggests stronger demand and better cost control. Sight Sciences Reports Second Quarter 2026 Financial Results
Positive Sentiment: FDA cleared OMNI Ultra: The new minimally invasive glaucoma surgery system is designed to perform single-pass canaloplasty followed by trabeculotomy. Its commercial U.S. launch remains planned for the fourth quarter of 2026, creating a potential future product and revenue catalyst. Sight Sciences Receives FDA Clearance of OMNI Ultra
Positive Sentiment: Broader reimbursement support: Aetna updated its commercial glaucoma policy to recognize Sight Sciences’ OMNI and SION systems as medically necessary for eligible mild-to-moderate open-angle glaucoma patients, potentially improving physician adoption and access. Sight Sciences Announces Aetna Coverage
Negative Sentiment: Profitability remains a risk: Despite the earnings beat, SGHT continues to report a net loss, negative margins, and negative return on equity. Investors will likely focus on whether revenue growth and expense controls can move the company toward sustainable profitability.

Sight Sciences Company Profile

(Get Free Report)

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.